Speciality Medicines FY26 net profit rises 81% to ₹1,303.29 lakh
Speciality Medicines reported an 81.1% rise in FY26 net profit to ₹1,303.29 lakh, driven by a 29.2% increase in revenue to ₹7,528.51 lakh. The Board approved audited results on May 28, 2026, confirming an unmodified opinion from auditors M/s. A K Ostwal & Co. The company utilized ₹509.15 lakh of its ₹2,914 lakh IPO proceeds, with no tax provision due to startup benefits under Section 80-IAC.
*this image is generated using AI for illustrative purposes only.
Speciality Medicines reported an 81.1% increase in net profit to ₹1,303.29 lakh for the financial year ended March 31, 2026, compared to ₹719.63 lakh in the previous year. Revenue from operations rose 29.2% to ₹7,528.51 lakh from ₹5,827.14 lakh in FY25. The Board of Directors approved the audited standalone financial results for the year and half-year ended March 31, 2026, in a meeting held on May 28, 2026.
The company’s total income for FY26 stood at ₹7,611.43 lakh, up from ₹5,853.97 lakh in the prior year. Total expenses increased to ₹6,309.55 lakh from ₹4,984.96 lakh. Profit before tax for the year was ₹1,301.88 lakh, a significant increase from ₹869.01 lakh in FY25. The statutory auditors, M/s. A K Ostwal & Co, issued an audit report with an unmodified opinion on the financial results.
Financial Performance
The half-year ended March 31, 2026, also showed strong performance, with net profit reaching ₹818.27 lakh compared to ₹268.36 lakh in the corresponding period of the previous year. Revenue for this half-year was ₹4,478.34 lakh. Basic earnings per share (EPS) for the full year improved to ₹20.11 from ₹11.79 in the previous year.
| Metric | FY26 (₹ in Lakh) | FY25 (₹ in Lakh) | Change |
|---|---|---|---|
| Revenue from Operations | 7,528.51 | 5,827.14 | Increase |
| Total Income | 7,611.43 | 5,853.97 | Increase |
| Total Expenses | 6,309.55 | 4,984.96 | Increase |
| Net Profit | 1,303.29 | 719.63 | Increase |
| Basic EPS | ₹20.11 | ₹11.79 | Increase |
IPO Proceeds Utilization
During the year, the company completed an Initial Public Offer (IPO) of 23,50,000 equity shares at an issue price of ₹124 per share, aggregating to ₹2,914 lakh. The shares were listed on the SME Platform of BSE Limited on March 30, 2026. As of March 31, 2026, the company utilized ₹509.15 lakh of the issue proceeds. The statutory auditors certified that the utilization was in line with the objects of the issue stated in the prospectus dated March 25, 2026, and complied with SEBI (ICDR) Regulations, 2018.
Segment and Taxation Details
Speciality Medicines operates a single reportable segment, the marketing and distribution of finished pharmaceutical formulations. The company obtained startup recognition from the Department for Promotion of Industry and Internal Trade, allowing for a 100% deduction of profit from startup business for three consecutive assessment years under Section 80-IAC. Consequently, no tax provision was made for FY 2024-25 and FY 2025-26, with tax calculated based on Minimum Alternate Tax (MAT).
Historical Stock Returns for Speciality Medicines
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.49% | -4.08% | -35.80% | +76.33% | +76.33% | +76.33% |
How does the company plan to deploy the remaining ₹2,404.85 lakh in IPO proceeds to sustain this growth trajectory?
What is the projected financial impact once the 100% tax deduction under Section 80-IAC expires after the three-year period?
Will the company diversify beyond the single reportable segment of marketing and distribution to include manufacturing?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
